The impact of SARS-Cov-2 infection on the periocular injection pain and hypersensitive reaction to botulinum toxin type A: results from clinical questionnaires
Description
CONCLUSION: Administering botulinum toxin type A three weeks after COVID-19 recovery is a justifiable and comparatively secure approach.
